Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 269

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 269
---
,726 26,388 Total operating lease liabilities$28,793 $30,563 

13

As of June 30, 2025, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):Years ending December 31,Sublease IncomeOperating Lease Liabilities 2025 (remaining)$3,064 $3,658 20266,342 6,591 20276,564 6,535 20286,794 6,520 20297,031 6,423 Thereafter9,160 8,760 Total$38,955 38,487 Less:Present value adjustment (9,694)Total $28,793 The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows: June 30, 2025December 31, 2024Weighted average remaining lease term5.3 years5.9 yearsWeighted average discount rate9.5%10.1%CommitmentsWe have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B. As of June 30, 2025, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled $79.1 million, which are expected to be paid through 2029. In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators as well as clinical material manufacturers. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period. ContingenciesFrom time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect